¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"mixed lymphocyte response"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • mixed hearing loss
    È¥ÇÕ³­Ã»
  • mixed indicator
    È¥ÇÕÁö½Ã¾à
  • mixed infection
    È¥ÇÕ°¨¿°
  • mixed joint
    ¹µÃà°üÀý, ´ÙÃà°üÀý
  • mixed nerve
    È¥ÇսŰæ
  • mixed order reaction
    È¥ÇÕ¼ø¼­¹ÝÀÀ
  • mixed pineocytoma
    È¥ÇÕ¼Ö¹æ¿ï»ùÁ¾, È¥ÇÕ¼Û°úüÁ¾
  • mixed psychosis
    È¥ÇÕÁ¤½Åº´
  • mixed tumor
    È¥ÇÕÁ¾¾ç
  • mixed vaccine
    È¥ÇÕ¹é½Å
  • arousal response
    °¢¼º¹ÝÀÀ
  • autoimmune response
    ÀÚ°¡¸é¿ª¹ÝÀÀ
  • alerting response
    °¢¼º¹ÝÀÀ
  • anamnestic response
    ¸é¿ª±â¾ï¹ÝÀÀ
  • biologic response modifier
    »ý¹°ÇÐÀû¹ÝÀÀÁ¶ÀýÁ¦, »ýü¹ÝÀÀÁ¶Àý¹°Áú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • mixed density
    È¥Çչеµ
  • mixed connective tissue disease
    È¥ÇÕ°áÇÕÁ¶Á÷º´, ½Â¸ðÆÇ¸·º´
  • mixed episode
    È¥Àç»ðÈ­
  • mixed gallstone
    È¥ÇÕ¾µ°³µ¹, È¥ÇÕ´ã¼®
  • mixed gland
    È¥ÇÕ»ù
  • mixed hearing loss
    È¥ÇÕ³­Ã»
  • mixed indicator
    È¥ÇÕÁö½Ã¾à
  • mixed infection
    È¥ÇÕ°¨¿°
  • mixed beam irradiation
    È¥ÇÕºöÁ¶»ç
  • mixed joint
    È¥ÇÕ°üÀý
  • mixed nerve
    È¥ÇսŰæ
  • mixed pineocytoma
    È¥ÇÕ¼Ö¹æ¿ï»ùÁ¾
  • mixed psychosis
    È¥ÀçÁ¤½Åº´
  • mixed sequence
    º¹ÇÕ¿¬¼â
  • mixed spicule
    È¥ÇÕħ°ñ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • antibody response
    Ç×ü¹ÝÀÀ(¡­Úãëë).
  • approximate response
    ±Ù»ç¹ÝÀÀ
  • arousal reaction=arousal response
    °¢¼º¹ÝÀÀ(ÊÆá¥Úãëë)
  • frenquency response curve
    Á֯ļö ¹ÝÀÀ°î¼±
  • galvanic skin response =GSR
    Àü±âÇǺιÝÀÀ(ï³Ñ¨ù«Ý±Úãëë).
  • galvanic skin response audiometry
    ÇǺÎÀü±â¹ÝÀÀ û·Â°Ë»ç
  • heat shock response
    ¿­Ãæ°Ý¹ÝÀÀ
  • ideosyncratic drug response
    ƯÀ̼º ¾à¹° ¹ÝÀÀ
  • immune response
    ¸é¿ªÀÀ´ä.
  • immune response
    ¸é¿ª¹ÝÀÀ
  • immune response
    ¸é¿ªÀÀ´ä.
  • immune response
    ¸é¿ªÀÀ´ä.
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ.
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ
  • immune response suppression
    ¸é¿ª¹ÝÀÀ¾ïÁ¦<--¾ï¾Ð>
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • lymphocyte production
    ¸²ÇÁ±¸»ý¼º
  • lymphocyte proliferation
    ¸²ÇÁ±¸Áõ½Ä
  • lymphocyte transformation
    ¸²ÇÁ±¸Àüȯ(¡­Ï¹ ï®üµ).
  • lymphocyte, resident
    »óÁÖ¸²ÇÁ±¸
  • lymphocyte-activating determinant
    ¸²ÇÁ±¸È°¼º °áÁ¤±â
  • lymphocyte-derived chemotactic factor
    ¸²ÇÁ±¸À¯·¡ È­ÇÐÁÖ¼ºÀÎÀÚ
  • lymphocyte-detected membrane antigen
    ¸²ÇÁ±¸-°ËÃâ ¼¼Æ÷¸·Ç׿ø
  • medium sized lymphocyte
    Á߸²ÇÁ±¸(ñ顭Ϲ).
  • medium sized lymphocyte
    Á߸²ÇÁ±¸(Ì¡?Ë´).
  • medium-sized lymphocyte
    Áß°£¸²ÇÁ±¸
  • monocyte lymphocyte ratio
    ´Ü±¸¸²ÇÁ±¸ºñ(ӤϹ¡­Ï¹Ýï).
  • monocyte lymphocyte ratio
    ´Ü±¸¸²ÇÁ±¸ºñ(ËÀË´?Ë´ËÓ).
  • primed lymphocyte
    ÃÊȸ°¨ÀÛ ¸²ÇÁ±¸
  • primed lymphocyte typing
    ÃÊȸÇ׿øÀÚ±ØÈÄ ¸²ÇÁ±¸Çüº°È­
  • primed lymphocyte-typing test
    ÃÊȸ°¨ÀÛ ¸²ÇÁ±¸ÀÌ¿ë Çüº°°Ë»ç
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • immune response gene
    ¸é¿ª ´ëÀÀ À¯ÀüÀÚ(Øóæ¹Óßëëë¶îîí­)
  • lysogenic response
    ¿ë¿ø´ëÀÀ(éÁê«Óßëë)
  • lytic response
    ¿ëÇØ´ëÀÀ(éÁú°Óßëë)
  • memory response
    ±â¾ï´ëÀÀ(ÑÀåãÓßëë)
  • phosphatidylinositol response
    Æ÷½ºÆÄƼµô ´ëÀÀ(Óßëë)
  • PI response
    PI ´ëÀÀ(Óßëë)
  • pleiotypic response
    ´Ù¸é ´ëÀÀ(ÒýØüÓßëë)
  • primary immune response
    ÀÏÂ÷ ¸é¿ª´ëÀÀ(ìéó­Øóæ¹Óßëë)
  • primary response
    ÀÏÂ÷ ´ëÀÀ(ìéó­Óßëë)
  • SOS response
    SOS ´ëÀÀ(Óßëë)
  • staircase response
    °è´Ü ´ëÀÀ(Í­Ó«Óßëë)
  • stringent response
    ¾ö°Ý ´ëÀÀ(åñÌ«Óßëë)
  • tertiary response
    »ïÂ÷´ëÀÀ (ß²ó­Óßëë)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
AMLC adherent macrophage-like cell; autologous mixed lymphocyte culture
AMLR autologous mixed lymphocyte reaction
MLI mesiolinguoincisal; mixed lymphocyte interaction
MLTI mixed lymphocyte target interaction
CTL cervico-thoraco-lumbar; control; cytolytic C lymphocyte; cytotoxic T-lymphocyte
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
(MLR mixed lymphocyte culture
MLR mixed lymphocyte culture reaction
MLR mixed leucocyte response
EMC Essential Mixed Cryoglobulinemia
MMMT Malignant Mixed Mesodermal Tumor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • mixed muscular vascular headache
    ±Ù¸Æ°ü¼º È¥ÇÕ µÎÅë, È¥ÇÕµÈ ±Ù-Ç÷°ü¼º µÎÅë, È¥ÇÕ¼º ±ÙÀ° Ç÷°ü µÎÅë, È¥ÇÕÇü ±Ù¸Æ°ü¼º µÎÅë
  • mixed odontogenic tumor
    È¥ÇÕ Ä¡¼º Á¾¾ç
  • mixed paralysis
    È¥ÇÕ ¸¶ºñ
    ¿îµ¿°ú °¨°¢ÀÇ ¿¬ÇÕ ¸¶ºñ.
  • mixed race
    È¥Ç÷ ÀÎÁ¾
  • mixed salivary gland
    º¹ÇÕ Ä§»ù, È¥ÇÕ Å¸¾×¼±
  • mixed small and large cell lymphoma
    È¥ÇÕ¼º ´ë¼Ò¼¼Æ÷ ¸²ÇÁÁ¾
  • mixed tumor
    È¥ÇÕÁ¾, È¥ÇÕ Á¾¾ç
    µ¿ÀǾî=
  • mixed vaccine
    È¥ÇÕ ¹é½Å
    µÎ Á¾·ù ÀÌ»óÀÇ ¿¹¹æÁ¢Á¾ Àç·á¸¦ È¥ÇÕÇÑ ¹é½Å. È¥ÇÕÇÔÀ¸·Î½á °¢ ¼ººÐÀÇ ¸é¿ª¿ø¼º¿¡ °¨¼ÕÀÌ ¾ø´Â °æ¿ì ÇàÇÏ¿©Áø´Ù. °¡Àå º¸ÆíÀûÀ¸·Î ¾²À̰í ÀÖ´Â °Í¿¡´Â ÀåÆ¼Çª½º¿Í ÆÄ¶óƼǪ½ºÀÇ È¥ÇÕ ¹é½Å, ÀÎÇ÷翣ÀÚ ¹ÙÀÌ·¯½ºÀÇ AÇü°ú BÇüÀÇ È¥ÇÕ ¹é½Å µîÀÌ ÀÖ´Ù. ÀåÆ¼Çª½º, ÆÄ¶óƼǪ½º È¥ÇÕ ¹é½ÅÀº ÀåÆ¼Çª½º±Õ°ú A±Õ ¹× ÆÄ¶óƼǪ½º B±ÕÀ» »ì±ÕÇÏ¿© ÀÏÁ¤ÇÑ ºñÀ²·Î È¥ÇÕÇÑ °ÍÀ¸·Î¼­, ÇÇÇÏ ÁÖ»ç ¶Ç´Â Çdz» ÁÖ»çÇÑ´Ù.
  • mixed venous blood
    È¥ÇÕ Á¤¸ÆÇ÷
  • monogerminal mixed tumor
    ´Ü ¹è¿±¼º È¥ÇÕ Á¾¾ç
  • odontogenic mixed tumor
    Ä¡¿ø È¥ÇÕ Á¾¾ç
  • adaptive response
    ÀûÀÀ ¹ÝÀÀ
    µ¿ÀǾî=ada
  • age-response function
    ¿¬·É ¹ÝÀÀ ÇÔ¼ö
  • alerting response
    °¢¼º ¹ÝÀÀ
  • amnestic response
    °Ç¸Á ¹ÝÀÀ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
mixed opioid agonist-antagonist <pharmacology> A compound that has an affinity for two or more types of opioid receptors and blocks opioid effects on one receptor type while producing opioid effects on a second receptor type.
(13 Nov 1997)
mixed paralysis Combined motor and sensory paralysis.
(05 Mar 2000)
mixed sleep apnoea <chest medicine> A form of sleep apnoea where there is exists a combination of obstructive and central sleep apnoea syndromes.
(13 Nov 1997)
mixed thrombus A laminated thrombus, the layers of different ages being of different colour or consistency.
Synonym: stratified thrombus.
(05 Mar 2000)
mixed tide <ecology, marine biology> Tidal cycle in which there are usually two high and two low tides during a day.
(13 Nov 1997)
mixed tumour A tumour composed of two or more varieties of tissue.
(05 Mar 2000)
mixed tumour, malignant A malignant tumour composed of more than one type of neoplastic tissue.
(12 Dec 1998)
mixed tumour, mesodermal A sarcoma of the body of the uterus arising in older women, composed of more than one mesenchymal tissue, especially including striated muscle cells. It is associated with previous pelvic radiation exposure in 20% of patients.
(12 Dec 1998)
mixed tumour, mullerian A tumour, basically a carcinoma with a single sarcoma such as leiomyosarcoma or angiosarcoma or multiple sarcomas of uterine origin. The role of oestrogen has been postulated as a possible aetiological factor in this tumour. (holland et al., cancer medicine, 3d ed, p1703)
(12 Dec 1998)
mixed tumour of salivary gland A tumour composed of salivary gland epithelium and fibrous tissue with mucoid or cartilaginous areas.
Synonym: pleomorphic adenoma.
(05 Mar 2000)
mixed tumour of skin <tumour> A benign tumour of sweat glands with a mucoid stroma showing cartilaginous metaplasia.
Synonym: mixed tumour of skin.
(05 Mar 2000)
neoplasms, complex and mixed Neoplasms composed of more than one type of neoplastic tissue.
(12 Dec 1998)
dentition, mixed The complement of teeth in the jaws after the eruption of some of the permanent teeth but before all the deciduous teeth are absent.
(12 Dec 1998)
lymphoma, mixed-cell Malignant lymphoma characterised by the presence of a mixed population of cells, with the smaller cells resembling lymphocytes and the larger ones histiocytes. It usually presents in a nodular (follicular) pattern, but may evolve into a diffuse pattern.
(12 Dec 1998)
lymphoma, mixed-cell, diffuse A heterogeneous group of intermediate-grade lymphomas of mixed cellular composition. Although they have not been extensively studied, it appears that they are predominantly B-cell diseases.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • mixed number
    ´ëºÐ¼ö
  • mixed tithe
    (°¡Ãà·ù¿¡¼­ÀÇ ¼öÀÍ¿¡ ´ëÇÑ) 10ºÐÀÇ 1ÀÇ ¼¼
  • mixed train
    (°´Â÷¿Í È­Â÷ÀÇ) È¥¼º ¿­Â÷
  • ready-mixed
    ¹Ì¸® Á¶Á¦(Á¶ÇÕ,È¥ÇÕ)ÇÑ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á